To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated
